Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on November 18, 2026
Isomorphic Labs raises $5 billion as Sellas reports AML survival benefit
MSD ended its nemtabrutinib program, AriBio reported a subgroup-only Alzheimer’s result, the FDA rejected Summit’s ivonescimab application and the EU authorized Rasonque for pancreatic cancer.
Today in brief
Isomorphic Labs secured $5 billion in a Series C round, while Sellas reported longer survival in a Phase 3 leukemia trial of its cancer vaccine.123 MSD stopped nemtabrutinib development after a safety review, and the FDA rejected Summit’s ivonescimab application over questions about whether trial results applied to U.S. patients.456
AriBio’s Alzheimer’s drug met the primary endpoint in a prespecified subgroup, not the full study population, and the European Commission authorized Revolution Medicines’ Rasonque for previously treated pancreatic cancer.78
Isomorphic Labs raises $5 billion for its AI drug pipeline
Isomorphic Labs raised $5 billion in a Series C led by Greenoaks Capital and Sequoia Capital.19 The financing came six months after the company raised $2.1 billion in a Series B round.910
Isomorphic said it will use the money to expand its AI drug-design platform, advance its pipeline and build clinical-development infrastructure.910 The company has reported positive preclinical findings in oncology and immunology, but its internal drug candidates remain before clinical testing.1011
Sellas reports longer survival with its leukemia vaccine
Sellas said galinpepimut-S lowered the risk of death by 41% in the Phase 3 REGAL trial for acute myeloid leukemia.23 Median overall survival was 24 months with the vaccine, compared with 14.7 months with investigator-selected treatment.23
The global, open-label trial randomized 126 patients in a second or later remission who were ineligible for stem cell transplant.3 Sellas plans to discuss an accelerated filing with the FDA and is preparing an application for the first half of 2027.3
MSD ends nemtabrutinib development after safety review
MSD stopped the Phase 3 BELLWAVE-011 trial and ended the broader nemtabrutinib program, including two other Phase 3 studies.4 An external Data Monitoring Committee advised that the drug’s potential benefits might not outweigh the risks seen in the data.4
After reviewing the full dataset, MSD said its safety assessment supported permanently ending the trial.4 The company is notifying investigators and advising enrolled patients to discuss treatment options with their doctors.4 MSD plans to share full study results after completing its analyses.4
AriBio’s Alzheimer’s drug met its endpoint in one trial subgroup
AriBio said its Phase 3 POLARIS-AD trial met its primary endpoint in the prespecified group taking AR1001 alone, but not in the full study population.7 In that subgroup, the CDR-SB score difference was 0.44 points, reported as 31% slower clinical decline.7
Across all participants, the CDR-SB difference was not significant, and AR1001 did not significantly improve the ADAS-Cog 13 measure.7 Four people taking AR1001 and two taking placebo had fatal adverse events. Adverse events led 5.2% of AR1001 recipients to stop treatment.7 AriBio plans to submit the complete results to the FDA to guide its next steps.7
FDA rejects Summit’s ivonescimab application
The FDA issued Summit Therapeutics a complete response letter, rejecting ivonescimab’s application in its current form.56 The agency said it could not determine whether the progression-free survival benefit in the Phase 3 HARMONi trial applied to U.S. patients.5
North America and Europe accounted for 38% of participants, but patients in China accounted for 93% of progression-free survival events in the primary analysis.5 The trial met its progression-free survival endpoint but missed its overall survival endpoint.6
EU authorizes Rasonque for previously treated pancreatic cancer
The European Commission authorized Revolution Medicines’ Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one systemic treatment.8 The authorization allows once-daily oral use whether or not a tumor has an identified RAS mutation.8
It covers European Union member states, Liechtenstein, Iceland and Norway.8 Patient access will depend on national pricing, health-technology assessment and reimbursement decisions.8